Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

111In-ibritumomab tiuxetan

(... ih-brih-TOO-moh-mab ty-UK-seh-tan)
A radiolabeled monoclonal antibody used to find certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the diagnosis of other types of B-cell tumors. 111In-ibritumomab tiuxetan is made up of the monoclonal antibody ibritumomab plus the radioisotope indium In 111. It binds to a protein called CD20, which is found on B cells. A machine is used to find which cells in the body have taken up 111In-ibritumomab tiuxetan. 111In-ibritumomab tiuxetan is a type of radioimmunoconjugate. Also called 111In-Zevalin and indium In 111-ibritumomab tiuxetan.
Search NCI's Dictionary of Cancer Terms